Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Dr. Raman has succeeded Victoria Richon
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Subscribe To Our Newsletter & Stay Updated
